During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years ...

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training ...

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia ...